GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Current Deferred Revenue

Access Bio (XKRX:950130) Current Deferred Revenue : ₩0 Mil (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Access Bio's current deferred revenue for the quarter that ended in Mar. 2025 was ₩0 Mil.

Access Bio Current Deferred Revenue Historical Data

The historical data trend for Access Bio's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Current Deferred Revenue Chart

Access Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Access Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Access Bio Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Access Bio's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines